Description

Stryker’s Quiet Robotics Expansion: How Handheld Surgical Tech Is Unlocking the Next Growth Curve!

Stryker Corporation delivered strong financial results for both the fourth quarter and the full year 2025, demonstrating solid performance across all key financial metrics. Organic sales growth reached 11% for Q4 and 10.3% for the full year, surpassing $25 billion in sales. This growth was driven by robust demand across the company’s diverse product portfolio, particularly in its Neurocranial, Endoscopy, Instruments, and Trauma and Extremities businesses. The U.S. market showed an impressive organic growth rate of 11.2%, while international growth was 7.5%, indicating substantial expansion in areas like emerging markets, South Korea, and Japan. These regions continue to offer considerable growth opportunities for Stryker as it introduces successful U.S. products to international markets. The company also achieved remarkable earnings and cash flow performance despite challenges like tariff headwinds, delivering a second consecutive year of at least 100 basis points of adjusted operating margin expansion.